Nuvation Bio Inc. (NUVB) - Dilution Analysis
Visualizing historical and potential share dilution over time
Dilution Analysis
Risk Assessment Details
Summary
NUVB currently has 348M outstanding shares. with moderate dilution risk from 126M authorized shares representing 36.1% potential dilution. The company has significantly diluted shareholders by 38.99% over the past 2 years, indicating aggressive capital raising.
Share Structure Timeline
Historical Data Points
| Date | Event | Outstanding | Supply |
|---|---|---|---|
| May 04, 2026 |
10-Q filing | 348.2M shares outstanding |
350M | 130M |
| Nov 03, 2025 |
10-Q filing | 342.8M shares outstanding |
340M | 130M |
| Aug 07, 2025 |
10-Q filing | 342.3M shares outstanding |
340M | 130M |
| May 07, 2025 |
10-Q filing | 340.3M shares outstanding |
340M | 130M |
| Mar 06, 2025 |
10-K filing | 337.7M shares outstanding |
340M | 130M |
| Nov 06, 2024 |
10-Q filing | 336.6M shares outstanding |
340M | 130M |
| Aug 05, 2024 |
S-3 filing: This S-3 filing includes the issuance of shares of Class A common stock upon exercise of warrants and the resale of common stock and warrants by selling securityholders. |
250M | 130M |
| Aug 05, 2024 |
10-Q filing | 249.2M shares outstanding |
250M | 130M |
| May 14, 2024 |
10-Q filing | 247.2M shares outstanding |
250M | 4.2M |
| Feb 29, 2024 |
10-K filing | 218.0M shares outstanding |
220M | 4.2M |
| Nov 02, 2023 |
10-Q filing | 218.9M shares outstanding |
220M | 4.2M |
| Aug 03, 2023 |
10-Q filing | 218.9M shares outstanding |
220M | 4.2M |
| May 04, 2023 |
10-Q filing | 218.8M shares outstanding |
220M | 4.2M |
| Mar 15, 2023 |
10-K filing | 217.8M shares outstanding |
220M | 4.2M |
| Nov 03, 2022 |
10-Q filing | 218.4M shares outstanding |
220M | 4.2M |
| Aug 04, 2022 |
10-Q filing | 218.2M shares outstanding |
220M | 4.2M |
| May 09, 2022 |
10-Q filing | 218.1M shares outstanding |
220M | 4.2M |
| Mar 02, 2022 |
POS AM filing: This POS AM filing relates to the issuance of Class A common stock upon exercise of warrants and the offer and sale of common stock and warrants by selling securityholders. |
220M | 4.2M |
| Feb 28, 2022 |
10-K filing | 218.1M shares outstanding |
220M | 4.2M |
| Nov 10, 2021 |
10-Q filing | 217.8M shares outstanding |
220M | 4.2M |
| Aug 12, 2021 |
10-Q filing | 217.8M shares outstanding |
220M | 4.2M |
| May 25, 2021 |
POS AM filing: This is a prospectus for the issuance of up to 60,936,608 shares of Class A common stock, up to 5,787,472 shares of Class A common stock issuable upon exercise of warrants, and up to 995,833 warrants to purchase Class A common stock by the company and selling securityholders. |
220M | 4.2M |
| May 17, 2021 |
10-Q filing | 217.7M shares outstanding |
220M | 73M |
| Mar 29, 2021 |
S-1/A filing: This S-1/A filing relates to the issuance of up to 5,787,472 shares of Class A common stock upon exercise of warrants and the offer and sale of up to 60,936,608 shares of common stock and up to 995,833 private warrants by selling securityholders. |
15M | 73M |
| Mar 11, 2021 |
10-K filing | 3.6M shares outstanding |
3.6M | 72M |
| Mar 11, 2021 |
S-1 filing: This is an S-1 filing for the issuance of Class A common stock upon exercise of warrants and the offer and sale of common stock and private warrants by selling securityholders. |
15M | 72M |
| Nov 16, 2020 |
10-Q filing | 14.9M shares outstanding |
15M | 4.2M |
| Oct 21, 2020 |
8-K filing: Panacea Acquisition Corp. entered into a merger agreement with Nuvation Bio Inc. and PIPE Investors subscribed for 47,755,000 shares of Panacea Class A common stock for $477,550,000. ($477.55M proceeds) |
15M | 4.2M |
| Aug 14, 2020 |
10-Q filing | 14.9M shares outstanding |
15M | 4.2M |
| Jul 10, 2020 |
8-K filing: Panacea Acquisition Corp. consummated its initial public offering of 14,375,000 units at $10.00 per unit, generating gross proceeds of $143,750,000, and completed a private sale of 487,500 units to EcoR1 Panacea Holdings, LLC and PA Co-Investment LLC at $10.00 per unit, generating gross proceeds of $4,875,000. ($148.63M proceeds) |
3.6M | 4.2M |
| Jul 06, 2020 |
8-K filing: Panacea Acquisition Corp. consummated its initial public offering of 14,375,000 units at $10.00 per unit, generating gross proceeds of $143,750,000, and completed the private sale of 487,500 units to the Company's sponsor and an affiliate of one of the underwriters at $10.00 per unit, generating gross proceeds of $4,875,000. ($148.63M proceeds) |
3.6M | 4.2M |
| Jun 23, 2020 |
S-1/A filing: This S-1/A filing describes an offering of 12,500,000 units at $10.00 per unit, each unit consisting of one share of Class A common stock and one-third of one redeemable warrant to purchase one share of Class A common stock. |
3.6M | 4.2M |
| Jun 12, 2020 |
S-1 filing: This S-1 filing outlines an initial public offering of units, each consisting of one share of Class A common stock and one-third of one redeemable warrant, with a proposed offering amount of $125,000,000 by Panacea Acquisition Corp, a blank check company, plus a forward purchase agreement for an aggregate of 2,500,000 shares of Class A common stock and 833,333 redeemable warrants for $25,000,000. |
3.6M | 15M |